These authors have found that high BMAL1 protein expression correlates to non-responsiveness to anti-angiogenic therapy with bevacizumab in mouse models of colorectal cancer and CRC patients and to poor clinical outcome in CRC patients following bevacizumab treatment [59]. Here, BMAL1 is linked to colorectal carcinoma.